Bharat Biotech to make ‘variant proof’ vaccine, company got funding of Rs 149 crore
Hyderabad : The Coalition for Epidemic Preparedness Innovation (CEPI) said that it will give US $ 19.3 million or about Rs 149 crore to the vaccine maker Bharat Biotech International, Sydney University and Switzerland-based Excelgene SA. CEPI will give this amount for the development of ‘variant proof’ vaccine.
CEPI will take the initiative under its US$200 million program to advance the development of vaccines that provide comprehensive protection against COVID-19 variants and other beta coronaviruses. CEPI will support the funding as it seeks to establish a pre-clinical and clinical proof of concept for an adjuvant subunit vaccine to provide comprehensive protection against all corona variants of concern as well as future variants of the virus. has been designed.
CEPI will fund researchers to conduct activities including immunogen design, preclinical studies, manufacturing process development and Phase 1 clinical trials. CEPI CEO Richard Hatchett said that as repeated waves of corona infection remind us, we will have to live with the virus for many years to come. The threat of a new variant emerging that could evade the safety of our current vaccines. Therefore investing in R&D for variant-proof SARS-CoV-2 vaccines is a global health security imperative.
He further added that our partnership with Bharat Biotech, University of Sydney and Exelgene will advance the development of a vaccine candidate to protect against future forms of COVID-19, potentially contributing to long-term control of the virus. While Bharat Biotech MD Krishna Ella (Dr. Krishna Ella, Managing Director bharat-biotech) said that existing vaccines are safe and effective against the variants currently exposed, it is imperative that innovations for multi-epitope vaccines Where a single vaccine can protect against all future forms.
Professor James Trikas, from the Institute of Infectious Diseases, University of Sydney, said that our mission is to provide a safe, cheap and highly effective vaccine to combat current and future SARS-CoV-2 variants, and our international association is working to achieve this goal. Well prepared. Dr. Maria J. Worm, CEO, Excelgene, said that we are currently using a similar approach to generate multiple antigen preparations derived from protein variants of SARS-CoV-2 for COVID-19. He is to receive funding and scientific advice from the Coalition for Epidemic Preparedness Innovation (CEPI) along with the University of Sydney and Bharat Biotech. We hope and will contribute to the science for protein-based vaccines.